Reverse-Phase Ultra-Performance Chromatography Method for Oncolytic Coxsackievirus Viral Protein Separation and Empty to Full Capsid Quantification

Oncolytic virus immunotherapy is emerging as a novel therapeutic approach for cancer treatment. Immunotherapy clinical drug candidate V937 is currently in phase I/II clinical trials and consists of a proprietary formulation of Coxsackievirus A21 (CVA21), which specifically infects and lyses cells wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, James Z., Rustandi, Richard R., Barbacci, Damon, Swartz, Andrew R., Gulasarian, Amanda, Loughney, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Methods
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347376/
https://www.ncbi.nlm.nih.gov/pubmed/35387488
http://dx.doi.org/10.1089/hum.2022.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347376/
https://www.ncbi.nlm.nih.gov/pubmed/35387488
http://dx.doi.org/10.1089/hum.2022.013

Ejemplares similares